Apr 3, 2023 · Purpose: A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma.

Due to their immature nature, MDSCs are susceptible to modification or reduction by differentiating agents such as all-trans retinoic acid (ATRA) (4, 6, 7). ATRA, a vitamin A derivative, is part of the standard of care therapy for acute promyelocytic leukemia.

Feb 15, 2024 · In mouse models of mesothelioma and fibrosarcoma, ATRA reduces the number of peripheral MDSCs and it induces an interferon-driven inflammatory tumor micro-environment enriched in CD8 + T-cells. This results in the sensitization of tumor cells to …

Mar 1, 2017 · Here we show that ATRA reduces the expression of the immunosuppressive genes ARG1, NOX1, INOS, and PD-L1 in MDSCs. Additionally, we show that treatment of MDSCs with ATRA decreases MDSC’s ability to suppress T cell proliferation.

Jun 10, 2022 · It has been shown that all-trans retinoic acid (ATRA) can differentiate MDSCs into mature myeloid cells. However, whether ATRA suppression of MDSCs function could enhance PD-L1...

Mar 15, 2013 · Increased production of reactive oxygen species (ROS) is a functional characteristic of MDSC, and all trans retinoic acid (ATRA), a derivative of vitamin A, has been shown to induce MDSC differentiation by a glutathione synthase dependant mechanism (Nefedova et al., 2007).

Recent research has demonstrated that ATRA reduces the number of M-MDSCs, G-MDSCs, and tumor-associated macrophages (TAMs) in the spleen. Additionally, ATRA significantly decreases the expression of tumor-infiltrating G-MDSCs and pro-tumor immune suppression molecules (ARG1, iNOS, IDO, S100A8, and S100A9) . ATRA has also been used to enhance ...

We assessed the ability of all-trans retinoic acid (ATRA), as repurposed compound serving as host-directed therapy (HDT), to counteract the suppressive effects of myeloid-derived suppressor cells (MDSCs) obtained from active TB cases (untreated or during week one of treatment) on T-cell responsiveness.

Nov 15, 2007 · Recent studies have shown that all-trans retinoic acid (ATRA) had a potent activity in eliminating MDSC in cancer patients and in tumor-bearing mice. ATRA differentiates these cells into mature myeloid cells.

Apr 3, 2023 · Myeloid-derived suppressor cells (MDSC) limit the efficacy of immune checkpoint inhibitors (ICI), including anti–PD-1. We sought to target MDSCs using the differentiating agent all-trans retinoic acid (ATRA) to enhance the efficacy of the anti–PD-1 antibody pembrolizumab in anti–PD-1 naïve patients with stage IV melanoma.